Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
Upadhyaya HP
PubMed, Pare, Guillaum, et al
"With an increasing number of similar GLP-1 drugs now being used in clinical practice, for conditions ranging from type 2 diabetes and obesity to kidney disease, our findings highlight the potential for these existing drugs to be repurposed to treat the risk of 'no-reflow' in heart attack patients, offering a potentially life-saving solution," said University College London Professor David Atwell
Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease
Moreover, regulatory considerations will be primarily important to support these advancements that will make the nano-lipid carrier a promising delivery system to address health challenges
